Toulouse - CHU
Welcome,         Profile    Billing    Logout  
 33 Trials 
62 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GREILLIER, Laurent
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Active, not recruiting
2
43
Europe
Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080
MedSIR, Merck Sharp & Dohme LLC
Metastatic Thymic Carcinoma, Thymoma Type B3
07/24
01/26
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
01/25
01/25
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting
2
80
Europe, RoW
Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736
Centre Leon Berard, Groupe Français de Pneumo-Cancérologie
Large Cell Neuroendocrine Carcinoma of the Lung
09/28
09/29
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
MATISSE, NCT05742607 / 2022-001903-42: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma, Innate Pharma SA
Non Small Cell Lung Cancer
06/25
09/26
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Recruiting
2
68
Europe
Adagrasib
ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.
NSCLC Stage IV, KRAS P.G12C
10/25
03/26
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting
2
550
Europe
Durvalumab
UNICANCER, AstraZeneca
Small Cell Lung Carcinoma
01/27
03/29
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn
2
44
Europe
Brigatinib, Durvalumab
ETOP IBCSG Partners Foundation, Takeda
NSCLC, Stage III, ALK-rearrangement
09/24
09/24
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab

Active, not recruiting
N/A
200
Europe
Data collection
Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
04/25
04/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
REAL-MOOV-LUNG, NCT04934865: Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients :

Active, not recruiting
N/A
240
Europe
Patients treated for their lung cancer.
Institut Curie
Lung Cancer
10/26
10/26
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC

Active, not recruiting
N/A
413
Europe
Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)
Groupe Francais De Pneumo-Cancerologie, AstraZeneca
Non-Small Cell Lung Cancer
06/27
06/27
BIGAY-GAME, Laurence
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
01/25
06/29
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Active, not recruiting
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Active, not recruiting
2
43
Europe
Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080
MedSIR, Merck Sharp & Dohme LLC
Metastatic Thymic Carcinoma, Thymoma Type B3
07/24
01/26
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
01/25
01/25
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
LUNG-RESIST, NCT04222335: Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Recruiting
N/A
80
Europe
Blood samples
University Hospital, Toulouse, Institut National de la Santé Et de la Recherche Médicale, France, National Cancer Institute, France
Lung Cancer, Nonsmall Cell
12/28
12/28
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31
MAZIERES, Julien
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib with Binimetinib in BRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
12/24
03/26
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
STX-241 FIH, NCT06567015: Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Recruiting
1/2
171
Europe, US, RoW
STX-241
Pierre Fabre Medicament
Non-small Cell Lung Cancer (NSCLC)
11/27
07/30
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
DAMeGe, NCT06589414: Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study

Recruiting
N/A
171
Europe
Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)
Institut Claudius Regaud, Ligue contre le cancer, France
Solid Tumours
05/26
10/26
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
SLEEP_CTC, NCT05988970: Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients

Recruiting
N/A
27
Europe
Blood samples will be collected at two times before the treatment initiation:
Institut Claudius Regaud
Lung Cancer
09/25
09/25
MINER, NCT03514368: Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

Recruiting
N/A
520
Europe
Patients treated with immune checkpoint blockade
Institut Claudius Regaud
Solid Cancers
11/29
11/29
MIRACLE, NCT05732974: A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Recruiting
N/A
60
Europe
Resected non small cell lung cancer
University Hospital, Toulouse
Non-small Cell Lung Cancer Stage IIIA
11/25
10/26
LUNG-RESIST, NCT04222335: Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Recruiting
N/A
80
Europe
Blood samples
University Hospital, Toulouse, Institut National de la Santé Et de la Recherche Médicale, France, National Cancer Institute, France
Lung Cancer, Nonsmall Cell
12/28
12/28
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
DECIDE, NCT03958240: Deciphering Mechanisms Underlying Cancer Immunogenicity

Recruiting
N/A
900
Europe
Blood samples, tumor biopsy specimens and ascites samples will be collected.
Institut Claudius Regaud
Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3, Glioblastoma Multiforme of Brain Stem, Non Small Cell Lung Cancer, Anal Cancer
09/29
09/29
THOMAS, Quentin
ALICA, NCT06467175: The Benefits of Long-read High-throughput Genomic Sequencing for the Causal Diagnosis of Cerebellar Ataxias

Recruiting
N/A
210
Europe
blood sampling for high molecular weight DNA extraction
Centre Hospitalier Universitaire Dijon
Cerebellar Ataxias
03/27
03/27
RADIAL-VALID, NCT04261127: Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia

Recruiting
N/A
400
Europe
Genetic diagnosis (PMDA panel), Use of RADIAL algorithm
University Hospital, Strasbourg, France
Autosomal Recessive Cerebellar Ataxia
09/29
09/29
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31

Download Options